Literature DB >> 19466418

The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats.

Yi Zheng1, Mingwei Li, Yongfeng Zhang, Xuhua Shi, Luling Li, Mulan Jin.   

Abstract

Pulmonary arterial hypertension (PAH) is a severe clinical and pathophysiologic syndrome with no effective treatment at present. Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), has been applied widely to the treatment of connective tissue diseases with the effect of immunosuppressant. Its anti-proliferation has been found recently. Thereby, we tried to examine the effects of MMF on rats with PAH which was induced by monocrotaline injection, so as to investigate the mechanisms of treatment on PAH by MMF. The results substantiated that MMF therapy can alleviate thickening of pulmonary arterial walls and inhibit abnormal vascular remodeling, and the MPA concentrations which demonstrated efficacy in this study are within clinical applicable range, suggesting huge potentiality of MMF in the treatment of human PAH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19466418     DOI: 10.1007/s00296-009-0966-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

Review 1.  Pulmonary arterial hypertension.

Authors:  Harrison W Farber; Joseph Loscalzo
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

2.  Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat.

Authors:  Marleen H M Hessel; Paul Steendijk; Brigit den Adel; Cindy I Schutte; Arnoud van der Laarse
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-05-26       Impact factor: 4.733

Review 3.  The use of mycophenolate mofetil in transplant recipients.

Authors:  T S Mele; P F Halloran
Journal:  Immunopharmacology       Date:  2000-05

4.  Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio.

Authors:  Rainer Voisard; Levent Geçgüner; Regine Baur; Tina Herter; Vinzenz Hombach
Journal:  Int J Cardiol       Date:  2005-07-20       Impact factor: 4.164

5.  Effects of mycophenolic acid on endothelial cells.

Authors:  Yanfei Huang; Zhihong Liu; Haidong Huang; Hao Liu; Leishi Li
Journal:  Int Immunopharmacol       Date:  2005-06       Impact factor: 4.932

6.  Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats.

Authors:  Chihiro Suzuki; Masafumi Takahashi; Hajime Morimoto; Atsushi Izawa; Hirohiko Ise; Minoru Hongo; Yasushi Hoshikawa; Takayuki Ito; Hiroshi Miyashita; Eiji Kobayashi; Kazuyuki Shimada; Uichi Ikeda
Journal:  Biochem Biophys Res Commun       Date:  2006-08-28       Impact factor: 3.575

7.  In vitro prevention of cyclosporin-induced cell contraction by mycophenolic acid.

Authors:  Isabelle Dubus; Sandra Sena; Jean-Pierre Labouyrie; Jacques Bonnet; Christian Combe
Journal:  Life Sci       Date:  2005-06-22       Impact factor: 5.037

Review 8.  Pulmonary arterial hypertension: current therapeutic strategies.

Authors:  Aniket Puri; Michael D McGoon; Sudhir S Kushwaha
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2007-06

9.  Successful rescue therapy with mycophenolate mofetil in kidney transplantation improves the long-term graft survival.

Authors:  Jaanus Kahu; Aleksander Lõhmus; Madis Ilmoja; Ulle Kirsimägi; Gennadi Timberg; Ants Peetsalu
Journal:  Medicina (Kaunas)       Date:  2007       Impact factor: 2.430

10.  Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases.

Authors:  N Kasitanon; M Petri; M Haas; L S Magder; D M Fine
Journal:  Lupus       Date:  2008-01       Impact factor: 2.911

View more
  9 in total

Review 1.  Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment.

Authors:  Elisabetta Zanatta; Pamela Polito; Giulia Famoso; Maddalena Larosa; Elena De Zorzi; Elena Scarpieri; Franco Cozzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-22

Review 2.  Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.

Authors:  Jessica B Badlam; Todd M Bull
Journal:  Ther Adv Chronic Dis       Date:  2017-03-01       Impact factor: 5.091

Review 3.  Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.

Authors:  Elizabeth R Volkmann; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2016-11

4.  Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.

Authors:  Julie Morisset; Kerri A Johannson; Eric Vittinghoff; Carlos Aravena; Brett M Elicker; Kirk D Jones; Charlene D Fell; Helene Manganas; Bruno-Pierre Dubé; Paul J Wolters; Harold R Collard; Christopher J Ryerson; Brett Ley
Journal:  Chest       Date:  2016-11-03       Impact factor: 9.410

Review 5.  Should Renal Inflammation Be Targeted While Treating Hypertension?

Authors:  Sarika Chaudhari; Grace S Pham; Calvin D Brooks; Viet Q Dinh; Cassandra M Young-Stubbs; Caroline G Shimoura; Keisa W Mathis
Journal:  Front Physiol       Date:  2022-06-13       Impact factor: 4.755

6.  Effect of asiaticoside on endothelial cells in hypoxia‑induced pulmonary hypertension.

Authors:  Xiaobing Wang; Xueli Cai; Wu Wang; Yi Jin; Mayun Chen; Xiaoying Huang; Xiaochun Zhu; Liangxing Wang
Journal:  Mol Med Rep       Date:  2017-12-12       Impact factor: 2.952

7.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700

8.  Mycophenolate Mofetil in a Lupus Patient with Pulmonary Hypertension.

Authors:  Kirthi Machireddy; Zin Myint; Eric Dein; Stephen C Mathai; Philip Seo; Uzma Haque; Rebecca Manno; Homa Timlin
Journal:  Cureus       Date:  2018-01-29

Review 9.  An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Francesco Salton; Elisa Baratella; Paola Confalonieri; Pietro Geri; Riccardo Pozzan; Chiara Torregiani; Roberta Bulla; Marco Confalonieri; Marco Matucci-Cerinic; Michael Hughes
Journal:  Diagnostics (Basel)       Date:  2022-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.